{"id":"cerc-301","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2036513","moleculeType":"Small molecule","molecularWeight":"357.42"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CERC-301 works by binding to CD28, a receptor on T-cells, to prevent their activation and proliferation. This mechanism is intended to reduce inflammation and prevent autoimmune diseases. By inhibiting T-cell activation, CERC-301 may also have potential in treating cancer.","oneSentence":"CERC-301 is a monoclonal antibody targeting CD28 to modulate T-cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:50:47.445Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe psoriasis"},{"name":"Moderate to severe atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT01941043","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment","status":"COMPLETED","sponsor":"Avalo Therapeutics, Inc.","startDate":"2013-11","conditions":"Major Depressive Disorder","enrollment":1357},{"nctId":"NCT02459236","phase":"PHASE2","title":"A Study of Intermittent Doses of CERC-301 in MDD","status":"COMPLETED","sponsor":"Avalo Therapeutics, Inc.","startDate":"2015-06","conditions":"Major Depressive Disorder","enrollment":115}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CERC-301","genericName":"CERC-301","companyName":"Avalo Therapeutics, Inc.","companyId":"avalo-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CERC-301 is a monoclonal antibody targeting CD28 to modulate T-cell activation. Used for Moderate to severe psoriasis, Moderate to severe atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}